|
 |
Breast Cancer > Monoclonal Antibodies
The following information is about Monoclonal Antibodies.
Monoclonal Antibodies Defined
Antibodies produced by a single cell or its identical descendants, specific for a given antigen (foreign substance). Monoclonal antibodies manufactured in the laboratory are designed to seek out specific antigens on cancer cells as targets. They are being studied for their potential to transport chemotherapy and radiotherapy directly to a cancer (cell), thereby killing the cancer cell without damaging healthy tissue.
This definition is in context to Breast Cancer. See more contextual defintions for Monoclonal Antibodies.
Morphotek opens clinical sites in EU for phase II pancreatic cancer drug trial
Published August 27, 2008, 9:43 pm, PharmaBiz
Morphotek, Inc, a subsidiary of Eisai Corporation of North America, announced that it has opened clinical sites in the European Union (EU) as part of the company's MORAb-009 phase-II study.
Seattle Genetics to Present at Upcoming Investor Conferences
Published August 27, 2008, 6:33 am, Centre Daily Times
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics, will present at two upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website, www.seattlegenetics.com, under the "news and investor information" section.
Seattle Genetics to Present at Upcoming Investor Conferences
Published August 27, 2008, 6:00 am, Business Wire via Yahoo! Finance
BOTHELL, Wash.----Seattle Genetics, Inc. announced today that Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics, will present at two upcoming investor conferences.
Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Published August 27, 2008, 4:00 am, PR Newswire via Yahoo! Finance
Human Genome Sciences, Inc. today announced it has completed enrollment and initial dosing in BLISS-76, the second of two pivotal Phase 3 randomized clinical trials of LymphoStat-B® in patients with active systemic lupus erythematosus .
ImmunoGen, Inc. Announces Webcast of Presentation at the Thomas Weisel Partners Healthcare Conference 2008
Published August 27, 2008, 3:59 am, Centre Daily Times
ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the Thomas Weisel Partners Healthcare Conference 2008 will be webcast live. The presentation is scheduled to begin at 11:30 a.m. EDT on September 3, 2008, and will be given at the Four Seasons Boston hotel. The presentation will provide an update on ImmunoGen.
ImmunoGen, Inc. Announces Webcast of Presentation at the Thomas Weisel Partners Healthcare Conference 2008
Published August 27, 2008, 3:30 am, Business Wire via Yahoo! Finance
WALTHAM, Mass.----ImmunoGen, Inc. today announced that its presentation at the Thomas Weisel Partners Healthcare Conference 2008 will be webcast live. The presentation is scheduled to begin at 11:30 a.m.
Morphotek,(R) Inc. Expands Its Phase II Trial Site Selections in the European Union
Published August 26, 2008, 8:34 am, Centre Daily Times
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has opened clinical sites in the European Union (EU) as part of the company's MORAb-009 Phase II study. The study is evaluating MORAb-009, a monoclonal antibody to mesothelin, as a first-line treatment for patients with pancreatic cancer. The randomized, controlled, double-blinded trial will compare ...
Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
Published August 26, 2008, 6:00 am, Centre Daily Times
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2 clinical trial in patients with advanced prostate cancer randomized to treatment with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone has commenced patient enrollment. IMC-A12 and IMC-1121B are ...
Morphotek,(R) Inc. Expands Its Phase II Trial Site Selections in the European Union
Published August 26, 2008, 6:00 am, Business Wire via Yahoo! Finance
EXTON, Pa.----Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, today announced that it has opened clinical sites in the European Union as part of the company's MORAb-009 Phase II study.
Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
Published August 26, 2008, 4:00 am, Business Wire via Yahoo! Finance
NEW YORK----ImClone Systems Incorporated , a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2 clinical trial in patients with advanced prostate cancer randomized to treatment with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone has commenced patient enrollment.
Are you looking for additional Breast Cancer > Monoclonal Antibodies news? Try our new "Monoclonal Antibodies News Focus" area.
Off-site Monoclonal Antibodies Links, User Submitted
The following links have been collected through user bookmark submission in the Monoclonal Antibodies category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
Tue Aug 5
Sun Jul 6
- Differences in KRAS Mutation Spectrum in Lung Cancer Cases between African Americans and Caucasians after Occupational or Environmental Exposure to Known Carcinogens -- Hunt et al. 11 (11): 1405 -- Cancer Epidemiology Biomarkers & Prevention: ... mutation frequency observed in African Americans. KRAS mutations are associated with poorer response to monoclonal antibody therapy. And the policians want to keep menthol c
Mon Jun 30
Tue May 13
Fri May 2
Tue Apr 8
- BioSpectrum - Singapore's BTI signs pact with Raven to develop new medicine of future: Better article, more concise and detailed then the one I posted yesterday.
Sun Mar 30
- (WO/2007/14712 2) MONOCLONAL ANTIBODIES THAT SELECTIVELY RECOGNIZE METHAMPHETAMIN E AND METHAMPHETAMIN E LIKE COMPOUNDS: Monoclonal antibodies for methamphetamin e and mdma patent
Wed Mar 26
- PHF-tau Antibodies for Neuroscience (ThermoFisher)
- Interferon gamma (IFNg) Assay Kits and Reagents (ThermoFisher)
If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Monoclonal Antibodies. If you would like to find related tags we recommend Tag Patterns > Monoclonal Antibodies
Off-site Monoclonal Antibodies Research Links
If you still need additional information on Monoclonal Antibodies then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
- A9 > Monoclonal Antibodies
- Alexa > Monoclonal Antibodies
- Anti-Aging Revolution > Monoclonal Antibodies
- DMOZ > Monoclonal Antibodies
- Feeds Filtered > Monoclonal Antibodies
- Google > Monoclonal Antibodies
- News Meme > Monoclonal Antibodies
- Nuah: News > Monoclonal Antibodies
- The Feed Directory > Monoclonal Antibodies
- OBP > Monoclonal Antibodies
- Open Tag Directory > Monoclonal Antibodies
- Podzy > Monoclonal Antibodies
- Yahoo > Monoclonal Antibodies
Breast Cancer Topics
Everything you need to know about Breast Cancer
Breast Cancer
If you know the Breast Cancer Term Name use the links below to quickly jump to your desired focus.
Bookmark Us
The On Topic Network
This website is part of The On Topic Network.
Thank You
Breast-Cancer.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.
Best Viewed With
License
This work is licensed under Creative Commons.